Current Report Filing (8-k)
August 04 2021 - 09:24AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of Earliest Event Reported): August 4,
2021
REDHAWK HOLDINGS CORP.
(Exact
name of registrant as specified in its charter)
Nevada |
000-54323 |
20-3866475 |
(State
or other jurisdiction of incorporation) |
(Commission
File Number) |
(Employer
Identification No.) |
|
|
|
100 Petroleum Drive, Suite 200, Lafayette, Louisiana
70508
|
(Address
of principal executive offices) (Zip Code) |
Registrant’s
telephone number, including area code: (337)
269-5933
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
RedHawk Medical Products and Services, LLC (“RHMP”), a wholly-owned
subsidiary of RedHawk Holdings Corp. (the “Registrant”, “we” or
“us”), entered into an Exclusive Distribution Agreement on July 28,
2021 (the “Agreement”) with a Texas-based medical device
distributor (“Distributor”), for the exclusive global distribution
of RHMP’s line of needle incineration devices (“SANDD™”).
Under the Agreement, the Distributor has committed, among other
things, to purchase from RHMP, a minimum of 44,500 SANDD
mini™, SANDD HP™ or SANDD FR™ needle incineration
devices, 35,000 SANDD Pro™ needle incineration devices, and
certain other medical supplies. The five-year Agreement (with a
three year extension if both parties agree) with annual renewals,
provides that RHMP will sell the SANDD™ devices to the
Distributor at its customary distributor prices. The Agreement can
be terminated by either party during the term at the end of each
anniversary of the Agreement, if either party provides the other at
least 30 days prior notice. The Agreement may also be terminated
upon the breach of either party (after a 14 day cure period),
including if certain required minimum sales are not met, and for
certain other reasons. The Agreement includes customary
intellectual property, confidentiality and non-compete
requirements.
RHMP
expects the initial orders from the Distributor to commence during
the three month period ending September 30, 2021, with the
Distributor’s initial marketing efforts focused on sales into
certain mutually agreed upon international territories.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REDHAWK HOLDINGS CORP. |
|
|
Date:
August 4, 2021 |
By: |
/s/
G. Darcy Klug |
|
|
G.
Darcy Klug |
|
|
Chief
Financial Officer |
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From Apr 2022 to May 2022
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From May 2021 to May 2022